Phase I Study of the Metabolism and Excretion of [14C]-Rigosertib After Single-dose Administration as 24-hour Continuous Intravenous Infusion to Healthy Volunteers

Trial Profile

Phase I Study of the Metabolism and Excretion of [14C]-Rigosertib After Single-dose Administration as 24-hour Continuous Intravenous Infusion to Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs Rigosertib (Primary)
  • Indications Cancer; Haemoblastosis
  • Focus Pharmacokinetics
  • Sponsors Onconova Therapeutics
  • Most Recent Events

    • 14 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrial.gov record.
    • 31 Jul 2015 Planned End Date changed from 1 Jul 2015 to 1 Nov 2015 as reported by ClinicalTrial.gov record.
    • 26 May 2014 Planned End Date changed from 1 Jul 2014 to 1 Jul 2015 as reported by ClinicalTrial.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top